Advertisement

Post-pandemic valuation models for technology buyouts

Omoize Fatimetu Dako
Advertisement

The COVID-19 pandemic fundamentally disrupted financial markets, rendering traditional valuation methodologies inadequate for assessing technology companies experiencing unprecedented volatility and permanent operational changes.

Advertisement

By mid-2022, as Omoize Fatimetu Dako settled into her role as Finance Manager at Clinical Research of Ontario, she was analyzing how crisis-driven transformation necessitates new frameworks for evaluating leveraged buyouts in technology sectors - frameworks that account for pandemic-specific risks while recognizing that some operational changes represent permanent rather than temporary shifts.

Dako's research examining post-pandemic LBO valuation reveals that traditional discounted cash flow models and comparable company analyses proved inadequate during 2020-2021, when pandemic conditions created divergent performance patterns across technology subsectors.

Enterprise software companies serving remote work solutions experienced dramatic growth, while hardware manufacturers faced supply chain disruptions that significantly impacted operations. This heterogeneity within the technology sector demanded more nuanced valuation approaches capable of distinguishing between temporary dislocations and permanent market evolution.

Her analysis, published in August 2022, proposes a comprehensive framework integrating pandemic-specific risk factors into traditional LBO models: supply chain disruption coefficients, remote work productivity adjustments, cybersecurity enhancement requirements, and liquidity premiums reflecting constrained exit markets.

Advertisement

The framework employs scenario-based modeling incorporating multiple growth trajectories and market condition assumptions, generating probability-weighted valuation ranges rather than point estimates that proved unreliable during volatile periods.

By this time in her career, Dako was managing financial operations for clinical research studies at Clinical Research of Ontario - work requiring her to develop and manage budgets for multi-site trials, review complex contracts identifying financial obligations and risk exposure, and implement financial controls ensuring accountability. Her experience navigating these complexities informed her thinking about how organizations assess risk and structure financial arrangements under uncertainty.

What distinguishes Dako's valuation framework is its emphasis on operational resilience assessment as critical to post-pandemic risk evaluation. Companies with established remote work capabilities and cloud-based infrastructure demonstrated superior pandemic performance compared to firms requiring significant operational adaptations.

Her framework incorporates operational resilience scoring based on technology infrastructure maturity, workforce distribution capabilities, and cybersecurity preparedness - factors that proved more predictive of transaction success than traditional financial metrics during the study period.

Dako also addresses how pandemic conditions altered exit strategy considerations for private equity firms. Public market volatility reduced IPO reliability as exit mechanism, while strategic acquisition markets became increasingly selective.

Advertisement

These constrained exit conditions required more conservative assumptions about holding periods and exit valuations, fundamentally altering risk-return profiles of technology LBO investments. Her framework includes flexible exit planning evaluating multiple scenarios including extended hold periods and secondary LBO transactions.

Her research acknowledges that technology subsectors exhibited distinct valuation patterns requiring specialized analytical approaches. Software-as-a-Service platforms experienced unprecedented demand growth but faced questions about sustainability as markets normalized. Fintech companies navigated intersecting technology innovation and financial services regulation, both disrupted by pandemic conditions.

Healthcare technology companies saw accelerated adoption while encountering new regulatory frameworks and reimbursement challenges. The framework's modular design enables customization for specific subsectors while maintaining consistent core principles.

Testing the framework against actual transaction outcomes demonstrated significant accuracy improvements compared to traditional models - 34% better performance when applied to a validation sample of 127 technology LBO transactions.

This empirical validation suggested that incorporating pandemic-specific risk factors and operational resilience assessments genuinely enhanced valuation reliability rather than simply adding complexity without corresponding benefit.

Advertisement

For Dako, this finding reinforced her conviction that financial models must evolve alongside business realities, incorporating new risk categories as they emerge rather than relying on historical frameworks that may no longer capture relevant factors driving value creation and destruction.

Advertisement